323 related articles for article (PubMed ID: 31425551)
1. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
Grau-Expósito J; Luque-Ballesteros L; Navarro J; Curran A; Burgos J; Ribera E; Torrella A; Planas B; Badía R; Martin-Castillo M; Fernández-Sojo J; Genescà M; Falcó V; Buzon MJ
PLoS Pathog; 2019 Aug; 15(8):e1007991. PubMed ID: 31425551
[TBL] [Abstract][Full Text] [Related]
2. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
[TBL] [Abstract][Full Text] [Related]
3. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
4. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
[TBL] [Abstract][Full Text] [Related]
5. Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.
Palermo E; Acchioni C; Di Carlo D; Zevini A; Muscolini M; Ferrari M; Castiello L; Virtuoso S; Borsetti A; Antonelli G; Turriziani O; Sgarbanti M; Hiscott J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413127
[TBL] [Abstract][Full Text] [Related]
6. Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections.
Yang H; Li X; Yang X; Lu P; Wang Y; Jiang Z; Pan H; Zhao L; Zhu Y; Khan IU; Shen Y; Lu H; Zhang T; Jiang G; Ma Z; Wu H; Zhu H
Antiviral Res; 2019 Sep; 169():104555. PubMed ID: 31295520
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
8. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
9. Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4
Kulpa DA; Talla A; Brehm JH; Ribeiro SP; Yuan S; Bebin-Blackwell AG; Miller M; Barnard R; Deeks SG; Hazuda D; Chomont N; Sékaly RP
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578289
[TBL] [Abstract][Full Text] [Related]
10. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C
J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485
[TBL] [Abstract][Full Text] [Related]
12. Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA.
Taylor JP; Armitage LH; Aldridge DL; Cash MN; Wallet MA
Biol Open; 2020 Dec; 9(12):. PubMed ID: 33234703
[TBL] [Abstract][Full Text] [Related]
13. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
14. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
[TBL] [Abstract][Full Text] [Related]
15. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
[TBL] [Abstract][Full Text] [Related]
16. A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4
Grau-Expósito J; Serra-Peinado C; Miguel L; Navarro J; Curran A; Burgos J; Ocaña I; Ribera E; Torrella A; Planas B; Badía R; Castellví J; Falcó V; Crespo M; Buzon MJ
mBio; 2017 Jul; 8(4):. PubMed ID: 28698276
[TBL] [Abstract][Full Text] [Related]
17. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
[TBL] [Abstract][Full Text] [Related]
18. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
19. Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4
Cao S; Slack SD; Levy CN; Hughes SM; Jiang Y; Yogodzinski C; Roychoudhury P; Jerome KR; Schiffer JT; Hladik F; Woodrow KA
Sci Adv; 2019 Mar; 5(3):eaav6322. PubMed ID: 30944862
[TBL] [Abstract][Full Text] [Related]
20. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
Suryawanshi P; Bagul R; Shete A; Thakar M
Front Immunol; 2021; 12():663919. PubMed ID: 33995393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
